GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Float Percentage Of Total Shares Outstanding

AP Biosciences (ROCO:6945) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jan. 18, 2025)


View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AP Biosciences's float shares is 0.00 Mil. AP Biosciences's total shares outstanding is 84.99 Mil. AP Biosciences's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AP Biosciences's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AP Biosciences's Institutional Ownership is 0.00%.


AP Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

AP Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/84.99
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AP Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences Headlines

No Headlines